View All

Eurofins Bioanalytical Services cross-validated a PK assay and three PD biomarker assays for a global trial involving pediatric patients with a rare inflammatory syndrome. The study used a monoclonal antibody biotherapeutic, with near real-time PK and PD data essential for understanding disease evolution during treatment.

You will learn the importance of shedding and infectivity assays in oncolytic viral trials, how qPCR and TCID50 assays provide key data on viral shedding, biodistribution, and infectivity, and the regulatory considerations for designing and validating these assays in clinical settings.

Check out the latest BioPharma Newsletter featuring how Eurofins Viracor targets precision oncology with the launch of PanCancer IQ™ and learn about new services and analytical techniques, research projects and other related topics. 

It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.

Check out the latest BioPharma Newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

Check out the latest Eurofins Viracor BioPharma Press Releases:

Check out the latest BioPharma Newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

Dec 1-3

RT-qPCR and Sequencing Testing Supporting SARS-CoV-2 Vaccine Clinical Trials

Presented By Mark Wissel

This informative webinar; featuring Karina Eterovic, PhD, R&D Director of Oncology Diagnostics at Eurofins Viracor, entitled: Exploring the application of comprehensive genomic profiling in oncology therapy development.

Sept 28 - Oct 1

qPCR/sequencing assay development to support vaccine clinical studies and trials

Presented by Mark Wissel